Loading organizations...
Loading organizations...
Sensome builds advanced medical technologies that embed proprietary tissue-sensing microchips into minimally invasive devices. These smart, connected instruments transform in situ bio-impedance measurements into real-time, actionable clinical insights. The core innovation allows physicians to receive precise, patient-specific information during procedures, with the Clotild® Smart Guidewire System being their initial application focused on acute ischemic stroke treatment.
The company was co-founded by Franz Bozsak, who serves as CEO, and Abdul Barakat, its Chief Scientific Advisor, emerging from Ecole Polytechnique in 2017. Bozsak holds a Ph.D. in Biomedical engineering, while Barakat is a distinguished CNRS Director of Research and an AXA Professor at Ecole Polytechnique. Their collaborative insight centered on leveraging bio-impedance technology to deliver immediate, data-driven intelligence at the point of care within interventional medicine.
Sensome targets physicians conducting minimally invasive procedures across various specialties, including neurovascular, lung cancer biopsy, and peripheral vascular intervention. The company's vision is to empower medical professionals with precise, real-time data, enabling faster and more effective treatment decisions. They aim to transform patient outcomes by bringing sophisticated, data-enabled smart medical devices into clinical practice.
Sensome has raised $17.0M across 3 funding rounds.
Sensome has raised $17.0M in total across 3 funding rounds.
Sensome is a medtech company developing breakthrough microchip technology that embeds tissue-sensing capabilities into minimally invasive medical devices, enabling real-time, patient-specific insights for physicians during procedures.[1][3] Its flagship product, the Clotild® Smart Guidewire System, targets acute ischemic stroke (AIS) treatment by differentiating clot composition via bio-impedance measurements, with applications expanding to lung cancer biopsies and peripheral vascular interventions; the system is manufactured by Asahi Intecc and advancing toward commercialization in the EU, US, and Japan.[1] Sensome serves interventional physicians and patients with conditions like stroke and cancer, solving the problem of imprecise, real-time tissue characterization during procedures to enable faster, data-driven decisions and improve outcomes in data-scarce environments.[1][2]
The company combines impedance-based sensors with AI/machine learning for versatile integration across devices, transforming in situ measurements into actionable insights; it has shown clinical feasibility in distinguishing healthy lung from cancerous tissue.[1][3][4]
Sensome emerged as a spin-off from Ecole Polytechnique, a leading French engineering school, leveraging academic research in AI-powered micro-sensors for medical applications.[3] Founded by a team including CEO Thomas Genoud (with a background in engineering and medtech innovation), the idea stemmed from pioneering impedance-based tissue-sensing technology to address gaps in real-time procedural intelligence.[1] Early traction included clinical feasibility studies validating the tech in stroke treatment and lung biopsies, culminating in partnerships like manufacturing with Asahi Intecc for Clotild and investments from firms such as Partech Partners, which back its revolutionary sensor-ML combo.[1][4]
Sensome stands out in interventional medtech through these key strengths:
Sensome rides the wave of AI-driven precision medicine and smart connected devices in interventional procedures, where real-time tissue data is transforming guesswork into data-driven care amid rising minimally invasive interventions.[1][2] Timing aligns with surging demand for stroke treatments (AIS affects millions annually) and oncology diagnostics, fueled by aging populations and post-pandemic focus on efficient, outcome-focused healthcare.[1] Market tailwinds include regulatory momentum for AI-medtech (e.g., EU/US approvals) and investor interest in spin-offs blending academia with commercial scale, as seen in Partech's portfolio.[4] Sensome influences the ecosystem by pioneering "smart sensing" standards, potentially accelerating adoption in vascular and oncology tools while enabling broader data ecosystems for procedural AI.[1][3]
Sensome is poised for commercial launches of Clotild in key markets (EU, US, Japan) by late 2020s, with expansion into peripheral and oncology applications driving revenue growth.[1] Trends like AI integration in medtech, rising stroke incidence, and demand for connected devices will propel it, potentially capturing share in the $10B+ neurovascular market. Its influence may evolve from niche innovator to platform leader, licensing tech to device makers and shaping data-driven interventional standards—echoing its origin as a polyvalent sensor pioneer empowering physicians at the point of care.[1][4]
Sensome has raised $17.0M in total across 3 funding rounds.
Sensome's investors include Kurma Partners.
Sensome has raised $17.0M across 3 funding rounds. Most recently, it raised $9.0M Series B in January 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2020 | $9.0M Series B | Kurma Partners | |
| Jun 1, 2018 | $5.0M Seed | Kurma Partners | |
| Jul 1, 2017 | $3.0M Seed | Kurma Partners |